NXLNasdaqElectromedical & Electrotherapeutic ApparatusUS GAAP · USD

Nexalin Technology, Inc.

Nexalin Technology, Inc. develops and commercializes non-invasive electrotherapy devices used in mental health and related therapeutic applications. The company sells devices, consumable supplies, and licensing or treatment-fee arrangements tied to customer use of its systems, with activity in the United States and overseas markets.

Kysy yhtiöstä
Liikevaihto0,3milj. USD
+78,8 %v/v
Liikevoitto (EBIT)−8,4milj. USD
−8,2 %v/v
EBIT-marginaali−2 781,7%
+1 814,4 %-yks.v/v
Nettotulos−8,2milj. USD
−8,1 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2021–2025

−10−8−6−4−202milj. USD2021: 0,14 milj. USD2021: EBIT −6,0 milj. USD20212022: 1,3 milj. USD2022: EBIT −1,8 milj. USD20222023: 0,11 milj. USD2023: EBIT −5,7 milj. USD20232024: 0,17 milj. USD2024: EBIT −7,8 milj. USD20242025: 0,30 milj. USD2025: EBIT −8,4 milj. USD20250,30−8,4
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Nexalin Technology, Inc.

Liiketoiminta

Osuus liikevaihdosta
Devices35 %

Electrotherapy systems sold for therapeutic use in clinical and other settings.

Equipment and Consumables40 %

Boards, electrodes, patient cables, and other hardware used with the device.

Licensing Fees15 %

Monthly licensing arrangements that allow customers to use the technology.

Treatment Fees and Supplies10 %

Usage-based treatment fees and recurring supply sales tied to installed systems.

Tuotteet

Raportoitu · osuus liikevaihdosta
45,1%29,5%16,3%9,1%FY2025100 %
  • Device Sales45,1 %
  • Equipment29,5 %
  • Licensing Fee16,3 %
  • Other9,1 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Nexalin sells to customers that operate or distribute therapeutic devices, including healthcare-related users and overseas buyers of equipment and systems. Its revenue model combines one-time equipment sales with recurring licensing and treatment-based fees, so customers buy both for access to the technology and for ongoing use of the device platform.

Healthcare and therapeutic users

Buy devices and related supplies for therapeutic use and ongoing patient treatments.

International equipment customers

Purchase boards, devices, and accessories for deployment outside the U.S.

License and treatment-fee customers

Pay recurring fees for access to the technology and for each treatment performed.

Strategia

Nexalin’s strategy centers on expanding commercialization of its device platform, including overseas sales, while continuing to serve existing U.S. customers. The company also emphasizes intellectual property protection, reimbursement coverage, and maintaining product safety and regulatory acceptance, all of which are important for adoption in healthcare markets.

Commercialize overseas marketsLyhyt aikaväli

International sales provide a path to revenue while U.S. approval and reimbursement are developed.

Obtain U.S. approval and reimbursement supportKeskipitkä aikaväli

U.S. market access and coverage are key to broader adoption in healthcare settings.

Protect intellectual property and product safetyPitkä aikaväli

Defending the technology and maintaining safety are central to competitive positioning and adoption.

Maantiede

Q1/2026

The company serves customers in the United States and also sells devices and equipment overseas. Reported revenue disclosures specifically mention shipments to China and a prior device sale to Oman, showing that international transactions can materially affect period-to-period results.

USA100 %

Riskit

Nexalin faces commercialization risk because adoption depends on regulatory approval, reimbursement, and competition from other therapies. The business is also exposed to foreign trade and tariff issues because it imports components and exports products, while its small scale and recurring operating losses increase financing and going-concern risk.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Going-concern and financing risk1Tariff and trade exposure2
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Going-concern and financing riskVaikutus: KriittinenTodennäköisyys: Korkea

    The company has limited cash resources and has relied on equity funding to support operations.

    Kohdistuu: Corporate liquidity

  2. Tariff and trade exposureVaikutus: KorkeaTodennäköisyys: Matala

    Imported components and exported products can be affected by tariffs or retaliatory trade actions.

    Kohdistuu: China and other export markets

  3. Regulatory approval riskVaikutus: Korkea

    U.S. device sales depend on obtaining and maintaining approval for the product.

    Kohdistuu: U.S. market access

  4. Reimbursement and coverage riskVaikutus: Korkea

    Healthcare adoption can be limited if payers do not cover the therapy adequately.

    Kohdistuu: Healthcare commercialization

  5. Competition from alternative therapiesVaikutus: Keskitaso

    Customers may choose other treatment modalities with stronger clinical or economic support.

    Kohdistuu: Therapeutic device market

Kysy Clarifolta: Nexalin Technology, Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition across devices, licensing, and treatment fees

Different contract types may recognize revenue at different times or based on usage.

Vaikutus: Affects reported revenue timing and quarterly comparability

Revenue mix and gross margin variability

Equipment sales, device sales, and licensing fees carry different margins.

Vaikutus: Can move gross profit materially from period to period

Fair value changes on short-term investments

Unrealized gains flow through other comprehensive income.

Vaikutus: Affects comprehensive loss and equity

Going-concern assessment

Liquidity assumptions and financing plans influence financial statement presentation.

Vaikutus: Important for evaluating solvency and disclosure risk

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

IR-Med, Inc.

Electromedical & Electrotherapeutic Apparatus

NexGel, Inc

NXGLW · Surgical & Medical Instruments & Apparatus

Neuronetics, Inc.

STIM · Surgical & Medical Instruments & Apparatus

Aclarion, Inc.

ACONW · Services-Medical Laboratories

RetinalGenix Technologies Inc.

RTGN · Surgical & Medical Instruments & Apparatus

Solana Co

HSDT · Finance Services

Päivitetty: 24.9.2026

Nexalin Technology, Inc. (NXL) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo